Anti-VEGF-A (L98) Antibody

Produced in rabbit and supplied at 1 mg/ml in phosphate buffered saline (PBS) with 0.05% sodium azide at approximately pH 7.2, this unconjugated polyclonal reagent from Antibodies.com targets the Vascular Endothelial Growth Factor A (VEGF-A) protein, a key signaling molecule driving angiogenesis, vascular permeability, and endothelial cell proliferation in both physiological and pathological contexts. Validated for Western Blot (WB) workflows across human, mouse, and rat samples, the antibody supports comparative studies of VEGF-A expression in cancer research, ischemic disease models, retinal pathology, and wound healing investigations.

Researchers commonly deploy this polyclonal reagent to detect endogenous VEGF-A isoforms in cell lysates and tissue homogenates, taking advantage of the polyclonal response to recognize multiple epitopes on the target. The 100 µl format supports multiple blotting experiments, and refrigerated storage in the supplied buffer preserves activity for routine laboratory use. Because VEGF-A upregulation is a hallmark of tumor angiogenesis and diabetic retinopathy, this antibody is frequently cited in oncology, ophthalmology, and cardiovascular research where quantitative protein-level readouts complement transcriptomic and pharmacological analyses of anti-angiogenic therapies, including studies involving bevacizumab and related small-molecule inhibitors of the VEGF signaling axis.